Track Castle Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Castle Biosciences, Inc. CSTL · Stock Open Castle Biosciences, Inc. in new tab

33.79 USD
EPS
-0.76
P/B
2.17
ROE
-4.87
Beta
0.95
Target Price
48.20 USD
Castle Biosciences, Inc. logo

Castle Biosciences, Inc.

🧾 Earnings Recap – Q1 2026

Castle Biosciences' shares fell 19.9% post-earnings, driven by investor disappointment likely tied to cautious 2026 revenue guidance given strong reported test volume growth, suggesting market skepticism about sustainability or margin pressures.

  • Q1 revenue reached $83.7 million, supported by 36% year-over-year growth in core test report volumes.
  • DecisionDx-Melanoma test reports grew 16% year-over-year, with March hitting a record month.
  • TissueCypher volumes surged 58% year-over-year, also achieving an all-time monthly high in March.
  • The company raised 2026 revenue guidance to $345-$355 million, a modest increase from prior guidance, reflecting cautious outlook despite strong volume gains.
  • New clinical data published and presented reinforce product differentiation but have not translated into more aggressive growth assumptions.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-0.76
Book Value15.55
Price to Book2.17
Debt/Equity7.64
% Insiders2.506%
Growth
Revenue Growth0.24%
Earnings Growth-0.52%
Estimates
Forward P/E-54.06
Forward EPS-0.63
Target Mean Price48.20

DCF valuation

Model fair value for Castle Biosciences, Inc. (CSTL)
Result
Sign in to run the valuation for CSTL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 48.20 USD (low 40.00, high 60.00) · as of 15 Nov 2026
Low 40.00
Mean 48.20
High 60.00
Price 33.79
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Castle Biosciences, Inc. Logo Castle Biosciences, Inc. Analysis (CSTL)

United States Health Care Official Website Stock

Is Castle Biosciences, Inc. a good investment? Castle Biosciences, Inc. (CSTL) is currently trading at 33.79 USD. Market analysts have a consensus price target of 48.20 USD. This suggests a potential upside from current levels.

Earnings Schedule: Castle Biosciences, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -0.63.

Investor FAQ

Does Castle Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Castle Biosciences, Inc.?

Castle Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -0.76.

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Exchange Ticker
NMS (United States) CSTL
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion